Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges ...

Barré for every million doses given.

Pfizer has had a difficult time in recent years as demand for its coronavirus products declined. The company’s share price has reflected the tough times, falling more than 50% over three years.

Kennedy Jr., a vaccine skeptic, as head of Health and Human Services (HHS ... s stock following the latest dip. Sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined steeply ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

The company's adjusted gross margin of 70% in Q3-24 reflects challenges from an unfavorable mix of COVID-19 products and royalty expenses but highlights ongoing cost control measures. Pfizer ...

Albert Bourla, Pfizer Chairman and Chief Executive Officer ... technology systems and infrastructure (including cloud services); any business disruption, theft of confidential or proprietary ...

To compensate for this and for the decline in coronavirus product sales, Pfizer began a record product launch process -- bringing to market 19 new products or indications in just 18 months. The ...